SAN DIEGO, CA., October 6, 2015— Acutus Medical, a global heart rhythm technology company, today presented data that demonstrated the ability of the AcQMap™ High Resolution Imaging and Mapping System to precisely overlay high-resolution dipole density (source charge) signals on an accurate ultrasound-based reconstruction of the left atrial chamber. The AcQMap system was able to provide a clearer picture of the patient’s heart rhythm. The initial study findings were presented during an oral presentation at the 10th annual Heart Rhythm Congress held in Birmingham, United Kingdom (UK) from October 4-7, 2015.

The abstract titled, “Novel Global Ultrasound Imaging and Continuous Dipole Density Mapping: Initial Findings In AF Patients” was presented by Dr. Patrick Heck, MD, PhD, Papworth Hospital, Cambridge, UK. The study evaluated the difference in ultrasound chamber reconstruction as compared to segmented CT scans and mapping clarity using dipole density instead of voltage in nine patients diagnosed with atrial fibrillation. The findings concluded that the AcQMap System reconstructed images of the atrium approached the quality of the CT scan. Additionally, dipole density mapping offered four times higher resolution of atrial activity than voltage.

“These data underscore the potential advantage the AcQMap System can provide to electrophysiologists (EPs) during AF procedures,” said Dr. Heck. “The image quality of the AcQMap System is unparalleled and allows us to visualize heart rhythms like never before. This is an impressive leap forward that opens the possibility to map AF with more precision to identify areas of interest as potential ablation targets.”

The AcQMap System can, for the first time, generate real-time, ultrasound images of the heart chamber with quality comparable to a CT or MRI in a matter of minutes. The System is the first and only to detect and display both standard voltage-based maps as well as the higher resolution dipole density maps through a set of proprietary algorithms. The result of combining highly accurate imaging with higher resolution mapping will enable EPs to identify and locate the tissue responsible for the arrhythmia, precisely target the area for treatment and minimize unnecessary heart ablations.

“Currently, most physicians rely on a strategy-based approach from years of experience and historical case statistics as they determine where and how to ablate within the heart chamber,” said Randy Werneth, President and Chief Executive Office of Acutus Medical. “The high-resolution images and dipole density information provided by our technology allows EPs, for the first time, to ‘see’ the
source and precise location of the arrhythmia and to treat according to real-time data. This conference was the perfect forum for Dr. Heck to share these data with the UK’s foremost EPs, as we are currently seeking CE mark approval in Europe and subsequent commercial placements at select centers.”

**About Acutus Medical**
Acutus Medical is a global heart rhythm technology company revolutionizing the way electrophysiologists (EPs) diagnose and treat cardiac arrhythmias. The company is currently pursuing CE mark approval in Europe for the full suite of AcQMap™ System products. Acutus Medical is a privately held company located in San Diego, CA. To learn more, visit [http://www.acutusmedical.com](http://www.acutusmedical.com).

**Forward Looking Statements**
This document includes forward-looking statements regarding Acutus Medical’s Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical’s goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.

**Media Contact:**
Susan Heins  
(864) 346-8336  
susan@purecommunicationsinc.com

**Investor Contact:**
Matt Clawson  
(949) 370-8500  
matt@purecommunicationsinc.com